Artursson group

Per Artursson

I am a professor of Dosage Form Design at the Department of Pharmacy, Uppsala University, Sweden where I head the Drug Delivery research team.  I am also Director for the Uppsala University drug optimization and pharmaceutical profiling platform within Science for Life Laboratories (UDOPP). Our research aims at understanding drug absorption, distribution, metabolism and excretion (ADME) at the molecular and cellular level in order to deliver drugs more effectively. We also investigate the effects of drug transporting proteins and drug metabolizing enzymes on cellular and subcellular drug disposition.  I have published about 250 research articles and reviews and supervised about 30 postdocs and 30 PhD students to completion. I am among the worlds most cited in my field, and have received several international awards for my research.

Per.Artursson@farmaci.uu.se

Elin Khan

Jacek Wisniewski

Jacek Wisniewski

Maria Karlgren

My research interests is in drug absorption, distribution, metabolism and elimination (ADME) with a focus on drug metabolizing enzymes, drug transport proteins, drug permeability, transport-metabolism interplay, drug-drug interactions, and on the development of predictive models for studying such processes. My current research program is focused on in vitro models for predicting drug delivery to the human brain.

Maria.Karlgren@farmaci.uu.se

Pär Matsson

I am Associate Professor at the Department of Pharmacy and a principal investigator in the Drug Delivery research team. I am also Program Director for the Master's Program in Pharmaceutical Modeling at the Faculty of Pharmacy. My research is centered on the development of new experimental and computational methods to quantitate and visualize drug distribution at the tissue, cellular and subcellular scales, and on applying these methods to understand how the chemical features of drug molecules determine their cellular transport and targeting to specific subcellular compartments. I am also very interested in how ligands outside the traditional small-molecule chemical space—in particular unusually large bioactive molecules—can be successfully developed into drugs.

Par.Matsson@farmaci.uu.se

Patrik Lundquist

My research focuses on permeability and transport mechanisms of drugs, metabolites, peptides and biologics in epithelia, primarily across the barriers of the human intestine. In collaboration with gastroenterologists from the Akademiska hospital in Uppsala we also investigate regional changes in intestinal barrier function in diverse patient groups.

Patrik.Lundquist@farmaci.uu.se

Rezvan Parvizi

My aim is to understand the rule of cellular drug disposition in pharmacological and toxicological outcome. To be specific, I am trying to couple the knowledge of transporters, metabolizing enzymes, and intracellular drug bioavailability to evaluate the risk for clinically significant drug-drug interactions. I am also trying to quantify antibiotics’ exposure to their targets and relate this pharmacologically active concentration to the observed antibacterial activity.

Rezvan.Parvizi@farmaci.uu.se

Andrea Treyer

In my PhD thesis I characterize parameters influencing intracellular bioavailability of drugs. For this, I make use of cellular systems transfected with single drug transporters and more complex cellular systems such as primary human heptaocytes (to study the combined effect of drug transporters and metabolism) or adipocytes derived from mouse fibroblast (to study the effect of intracellular lipid stores). I am developing prediction models for unspecific cellular binding of drugs based on cell-free assays.

Andrea.Treyer@farmaci.uu.se

Magnus Ölander

The general aim of my PhD thesis work is to improve the understanding of important model systems for studying drug disposition in the human small intestine and liver. The focus is mainly on liver cells, where I use global proteomics and various in vitro methods to study how hepatocytes react to handling and storage after isolation, as well as the roles that non-parenchymal liver cells play in hepatic drug disposition.

Magnus.Olander@farmaci.uu.se

Christine Wegler

For my PhD-thesis I investigate how obesity affects the human proteome, using targeted and global proteomics approaches. I focus on intestinal and hepatic proteins important for metabolism and transport of drugs. I also use different in vitro methods for predicting transport and metabolism of drugs in the body, and try to improve them with information from intracellular drug bioavailability and proteomics.

Christine.Wegler@farmaci.uu.se

Niklas Handin

My work focus on drug transporters and drug metabolizing enzymes influences on drug disposition. The project will explore new methods and approaches that could benefit drug discovery and development. A special attention will be on target (cancer) and off-target (normal liver) tissue.

Niklas.Handin@farmaci.uu.se

Signe Klinting

Signe Klinting

My PhD-project focuses on endocrine disrupting chemicals (EDCs). I investigate how the application of the intracellular bioavailability and global proteomics of the test systems can provide a deeper understanding of in vitro determined toxicity of these substances. This knowledge could potentially improve risk assessment of EDCs.

Signe.Klinting@farmaci.uu.se

Varun Maturi

Varun Maturi

My work involves answering basic cell biology questions using advanced chromatography techniques. My project involves de-orphanising novel transporters using proteomics and metabolomics approach. The focus of my research is on the therapeutic role of the solute carriers that are highly expressed in metabolically active organs like liver, intestine, kidney and brain.

Varun.Maturi@farmaci.uu.se

Laura Hellinen

My aim is to define whether age-related macular degeneration (AMD) affects the pharmacokinetics in the retina. For this, I compare intracellular bioavailability of drugs in normal retinal cells and disease-state retinal cells. I also study how the disease affects the retina with global proteomics approach. In addition, I am investigating a small set of promising compounds against dry AMD in disease-state retinal cells with cellular thermal shift assay coupled with analysis of the cellular proteome. By this, I aim to improve the understanding of the disease pathway and to identify novel drug targets against dry AMD.

Laura.Hellinen@farmaci.uu.se

Laura Kelsall

Laura Kelsall